BACKGROUND AND PURPOSE: To assess the ability of children with acute lymphoblastic leukemia (ALL) to develop an antibody response after influenza vaccination. METHODS: A total of 65 children under 15 years old were studied, including 25 children with ALL undergoing chemotherapy, 30 with asthma in remission who were regularly followed at clinics, and 10 healthy children. The influenza vaccine contained antigens B/Yamanashi/166/98, A/New Caledonia/20/99 (H1N1), and A/Panama/2007/99 (H3N2). RESULTS: Children with ALL developed significant antibody titers to A/Panama /2007/ 99 antigen 4 weeks after the second immunization. Seroconversion rates after two doses of vaccine were 57.1 to 84.6% and seroresponse rates were between 24 and 60% in children with ALL. Compared to children with asthma in remission, who were regarded as immunocompetent individuals, the ALL children had less seroconversion and lower seroresponse rates to A/New Caledonia/20/99 (H1N1). The seroconversion and seroresponse rates to B/Yamanashi/166/98 and A/ Panama/2007/99(H3N2) antigens were comparable in asthmatic and leukemic children. On the other hand, the antibody response in children with ALL who receivedreinduction chemotherapy suggests that the therapy did not impair seroresponse rates. CONCLUSION: Our data suggest that the influenza vaccine is safe and effective in children with either ALL or asthma in Taiwan.
RCT Entities:
BACKGROUND AND PURPOSE: To assess the ability of children with acute lymphoblastic leukemia (ALL) to develop an antibody response after influenza vaccination. METHODS: A total of 65 children under 15 years old were studied, including 25 children with ALL undergoing chemotherapy, 30 with asthma in remission who were regularly followed at clinics, and 10 healthy children. The influenza vaccine contained antigens B/Yamanashi/166/98, A/New Caledonia/20/99 (H1N1), and A/Panama/2007/99 (H3N2). RESULTS:Children with ALL developed significant antibody titers to A/Panama /2007/ 99 antigen 4 weeks after the second immunization. Seroconversion rates after two doses of vaccine were 57.1 to 84.6% and seroresponse rates were between 24 and 60% in children with ALL. Compared to children with asthma in remission, who were regarded as immunocompetent individuals, the ALL children had less seroconversion and lower seroresponse rates to A/New Caledonia/20/99 (H1N1). The seroconversion and seroresponse rates to B/Yamanashi/166/98 and A/ Panama/2007/99(H3N2) antigens were comparable in asthmatic and leukemicchildren. On the other hand, the antibody response in children with ALL who received reinduction chemotherapy suggests that the therapy did not impair seroresponse rates. CONCLUSION: Our data suggest that the influenza vaccine is safe and effective in children with either ALL or asthma in Taiwan.
Authors: Hana Hakim; Kim J Allison; Lee-Ann Van de Velde; Li Tang; Yilun Sun; Patricia M Flynn; Jonathan A McCullers Journal: Vaccine Date: 2016-04-26 Impact factor: 3.641
Authors: Charles R Beck; Bruce C McKenzie; Ahmed B Hashim; Rebecca C Harris; Arina Zanuzdana; Gabriel Agboado; Elizabeth Orton; Laura Béchard-Evans; Gemma Morgan; Charlotte Stevenson; Rachel Weston; Mitsuru Mukaigawara; Joanne Enstone; Glenda Augustine; Mobasher Butt; Sophie Kim; Richard Puleston; Girija Dabke; Robert Howard; Julie O'Boyle; Mary O'Brien; Lauren Ahyow; Helene Denness; Siobhan Farmer; Jose Figureroa; Paul Fisher; Felix Greaves; Munib Haroon; Sophie Haroon; Caroline Hird; Rachel Isba; David A Ishola; Marko Kerac; Vivienne Parish; Jonathan Roberts; Julia Rosser; Sarah Theaker; Dean Wallace; Neil Wigglesworth; Liz Lingard; Yana Vinogradova; Hiroshi Horiuchi; Javier Peñalver; Jonathan S Nguyen-Van-Tam Journal: PLoS One Date: 2011-12-22 Impact factor: 3.240
Authors: Rishi S Kotecha; Ushma D Wadia; Peter Jacoby; Anne L Ryan; Christopher C Blyth; Anthony D Keil; Nicholas G Gottardo; Catherine H Cole; Ian G Barr; Peter C Richmond Journal: Cancer Med Date: 2015-12-29 Impact factor: 4.452
Authors: Leslie S Kersun; Anne Reilly; Susan E Coffin; Jean Boyer; Eline T Luning Prak; Kenyetta McDonald; Xiaoling Hou; Abbas F Jawad; Kathleen E Sullivan Journal: Influenza Other Respir Viruses Date: 2012-11-30 Impact factor: 4.380